Zolgensma Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improvements in gene therapy delivery platforms, clinical success in treating SMA type 1, early diagnosis through newborn screening, regulatory support for gene therapies, expansion of pediatric neuromuscular care.

The growth in the forecast period can be attributed to increasing investment in gene therapy pipelines, expansion of newborn screening programs, rising demand for curative rare disease treatments, advancements in viral vector manufacturing, growing focus on long-term health economics benefits. Major trends in the forecast period include increasing adoption of one-time gene therapies, rising focus on early genetic intervention, growing use of viral vector technologies, expansion of curative treatment approaches, enhanced emphasis on long-term survival outcomes.

The increasing incidence of spinal muscular atrophy (SMA) is expected to drive the growth of the Zolgensma market. SMA is a genetic disorder that leads to the degeneration of motor neurons in the spinal cord, causing progressive muscle weakness and atrophy. It primarily affects infants and young children, potentially resulting in severe physical disabilities and life-threatening complications. The rising incidence of SMA is partly due to improved genetic testing and newborn screening programs, which allow for earlier and more accurate diagnosis, uncovering cases that might have previously gone undetected. Zolgensma addresses the underlying genetic cause by delivering a functional copy of the SMN1 gene, restoring production of the survival motor neuron (SMN) protein necessary for motor function and muscle strength, ultimately improving motor skills and survival in affected children. For instance, in August 2025, according to the NICE organization, SMA occurs in approximately 1 in 14,000 births worldwide, with around 47 babies born with SMA in the UK in 2023. Therefore, the increasing incidence of SMA is propelling the growth of the Zolgensma market.

Rising healthcare expenditure is also expected to support the growth of the Zolgensma market. Healthcare expenditure includes the total financial resources spent by governments, organizations, and individuals on prevention, treatment, and management of health conditions. Increasing expenditure is driven by advancements in medical technology, as new diagnostic tools and innovative therapies often carry high costs, raising overall healthcare spending. Higher healthcare expenditure facilitates access to advanced treatments like Zolgensma by enabling broader patient coverage and reimbursement. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, U.S. healthcare expenditures increased by 7.5% in 2023, reaching $4.9 trillion, or roughly $14,570 per individual. Therefore, rising healthcare expenditure is driving the growth of the Zolgensma market.

The rising prevalence of rare diseases is another factor expected to boost the Zolgensma market. Rare diseases affect a small portion of the population and often present unique challenges in diagnosis and treatment. Improved diagnostic tools and increased awareness have led to earlier detection of these conditions. Zolgensma addresses rare diseases like SMA by delivering a functional copy of the defective SMN1 gene, enabling production of the SMN protein essential for motor neuron survival and muscle function. For instance, in September 2024, according to the European Union, there are over 6,000 distinct rare diseases collectively affecting up to 36 million people across the EU. Therefore, the rising prevalence of rare diseases is driving growth in the Zolgensma market.

Major companies operating in the zolgensma market are Novartis AG.

North America was the largest region in the zolgensma market in 2025. The regions covered in the zolgensma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zolgensma market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the zolgensma market by increasing costs of imported viral vector production equipment, gene synthesis materials, sterile manufacturing systems, and ultra-cold storage logistics. Pediatric gene therapy markets in North America and Europe are most affected due to dependence on highly specialized international manufacturing inputs. These tariffs are raising overall therapy delivery costs and influencing reimbursement negotiations. However, they are also driving domestic gene therapy manufacturing investments, regional production capacity expansion, and strengthened local supply chains for advanced genetic medicines.

The zolgensma market research report is one of a series of new reports that provides zolgensma market statistics, including zolgensma industry global market size, regional shares, competitors with a zolgensma market share, detailed zolgensma market segments, market trends and opportunities, and any further data you may need to thrive in the zolgensma industry. This zolgensma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zolgensma is a gene therapy developed to treat spinal muscular atrophy (SMA), a rare genetic disorder that causes muscle weakness and loss of motor function. It works by replacing the defective or missing SMN1 gene in children under two years old, helping to restore motor function and improve survival outcomes.

The primary indications for Zolgensma include spinal muscular atrophy (SMA) type 1, type 2, type 3, and pre-symptomatic SMA. SMA type 1 is the most severe form, characterized by rapid degeneration of motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. Zolgensma is used in pediatric patients (infants and children) and adults, and is distributed through hospitals, specialty clinics, and pharmacies.

The zolgensma market consists of infusion sets, syringes, and other medical supplies for intravenous administration. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.